Turning high-cost drug and infusion visibility into responsible fiduciary action.

Group Benefit Systems, Inc.

Partnering with NIH has given Group Benefit Systems a powerful advantage in helping our clients address one of the fastest-growing drivers of healthcare costs—prescription drugs. Their innovative approach has enabled us to deliver measurable savings without compromising member access to the medications they need.

In an environment where traditional carrier and PBM models continue to drive higher costs, NIH has provided a refreshing alternative. Their transparent strategy, combined with their expertise in sourcing high-cost specialty medications, has allowed our clients to significantly reduce pharmacy spend while strengthening the overall financial health of their benefit plans.

NIH has become an important strategic partner for our organization. Together, we're delivering meaningful cost containment, improving plan performance, and creating better outcomes for employers and their employees.

Group Administrators

NIH has been a valuable partner in Group Administrators’ recent success. Through this partnership, we finally have meaningful leverage over one of the BUCAs’ greatest vulnerabilities: rising prescription drug spend.

As the BUCAs continue to vertically integrate their PBMs and navigate minimum loss ratio requirements, their traditional models are becoming increasingly uncompetitive. By combining NIH’s pharmacy cost-containment strategies with key stop-loss partnerships, we are helping employers achieve something rarely seen in healthcare—reverse cost trends.

The result is a true win for the plan, the employer, and its members.